Contact
searchSearch
HMP Global

Follicular Lymphoma Topic Center

News
Emerging Treatments Improve Outcomes for Patients With Relapsed/Refractory Follicular Lymphoma
03/21/2025
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
Recent advancements in...
03/21/2025
First Report Managed Care
News
Bispecific Antibody Therapy Achieves Sustained Remissions in Follicular Lymphoma
03/06/2025
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
A 3-year follow-up of a phase...
03/06/2025
First Report Managed Care
News
Targeting Expanded Follicular Regulatory T Cells Is a New Approach to Combat Follicular Lymphoma
08/26/2024
Follicular regulatory T cells (Tfr) are a potential target in treating follicular lymphoma (FL), the most common indolent B-cell lymphoma, according to study results published in Frontiers in Immunology.
Follicular regulatory T cells (Tfr) are a potential target in treating follicular lymphoma (FL), the most common indolent B-cell lymphoma, according to study results published in Frontiers in Immunology.
Follicular regulatory T cells...
08/26/2024
First Report Managed Care
News
New Treatment Options Benefit Patients With Relapsed/Refractory Follicular Lymphoma
08/05/2024
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with...
08/05/2024
First Report Managed Care
News
Sun Exposure Linked With Lower Risk of Follicular Lymphoma
07/30/2024
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer...
07/30/2024
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos

What's New?

News
Emerging Treatments Improve Outcomes for Patients With Relapsed/Refractory Follicular Lymphoma
03/21/2025
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
Recent advancements in...
03/21/2025
First Report Managed Care
News
Bispecific Antibody Therapy Achieves Sustained Remissions in Follicular Lymphoma
03/06/2025
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
A 3-year follow-up of a phase...
03/06/2025
First Report Managed Care
News
Targeting Expanded Follicular Regulatory T Cells Is a New Approach to Combat Follicular Lymphoma
08/26/2024
Follicular regulatory T cells (Tfr) are a potential target in treating follicular lymphoma (FL), the most common indolent B-cell lymphoma, according to study results published in Frontiers in Immunology.
Follicular regulatory T cells (Tfr) are a potential target in treating follicular lymphoma (FL), the most common indolent B-cell lymphoma, according to study results published in Frontiers in Immunology.
Follicular regulatory T cells...
08/26/2024
First Report Managed Care
News
New Treatment Options Benefit Patients With Relapsed/Refractory Follicular Lymphoma
08/05/2024
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with...
08/05/2024
First Report Managed Care
News
Sun Exposure Linked With Lower Risk of Follicular Lymphoma
07/30/2024
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer...
07/30/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use